OPUS GENETICS INC. - COMMON STOCK

1.1400

04-February-25 12:45:21

15 minutes delayed

Stocks

+0.0600

+5.56%

Today's range

1.0900 - 1.1800

ISIN

N/A

Source

NASDAQ

Ocuphire to Participate in March Investor Conferences

04 Mar 2021 08:27:09 By Nasdaq GlobeNewswire
Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia

18 Feb 2021 08:53:31 By Nasdaq GlobeNewswire
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021

11 Feb 2021 09:12:54 By Nasdaq GlobeNewswire
Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

20 Jan 2021 07:00:00 By Nasdaq GlobeNewswire
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

06 Jan 2021 07:00:01 By Nasdaq GlobeNewswire

<<
<
3
4
5
6
7
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.